申请人:Mitsubishi Tanabe Pharma Corporation
公开号:EP2390254A1
公开(公告)日:2011-11-30
Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group represented by formula: -NH-, or the like; ring A represents a 6-membered aromatic ring which may contain 1 to 2 nitrogen atoms as heteroatoms (the aromatic ring may be substituted by a halogen atom, a group represented by formula: -CONRaRb, or the like; Ra and Rb are the same or different and independently represent hydrogen, alkyl, hydroxyalkyl, or the like); R1 represents an acyl group or the like; and R2 represents a halogen atom or a cyano group.
揭示了一种新型吡咯并[2,3-d]嘧啶化合物,其表示为式[I]或其药理学上可接受的盐,具有GPR119受体激动活性,并且对制药有用。在式[I]中,E代表由式表示的基团:-NH-,或类似基团;环A代表可能含有1至2个氮原子作为杂原子的6元芳香环(芳香环可能被卤素原子、由式表示的基团:-CONRaRb,或类似基团取代;Ra和Rb相同或不同且独立地代表氢、烷基、羟基烷基,或类似基团);R1代表酰基团或类似基团;R2代表卤素原子或氰基。